Therapeutic efficacy of pyronaridine-artesunate (Pyramax®) against uncomplicated Plasmodium falciparum infection at Hamusit Health Centre, Northwest Ethiopia

Malaria Journal

Research

Woyneshet Gelaye¹  Megbaru Alemu Abate²  Habtamu Belay³  Mihreteab Alebachew⁴  Mebrahtom Haile⁵  Gudissa Assefa⁵  Jonathan B. Parr⁶  Bokretsion Gidey⁷  Henok Hailgiorgis⁷  Hussein Mohammed⁷  Geremew Tasew⁷  Heven Sime⁷  Ashenafi Assefa⁸  Worku Bekele⁹ 

[1] Department of Medical Laboratory Sciences, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia;Department of Medical Laboratory Sciences, College of Medicine and Health Sciences, Bahir Dar University, Bahir Dar, Ethiopia;The Unversity of Queensland, School of Public Health, Brisbane, Australia;Department of Medical Laboratory Sciences, College of Medicine and Health Sciences, Wolkite University, Wolkite, Ethiopia;Department of Medical Laboratory Sciences, College of Medicine and Health Sciences, Wollo University, P.O Box 1145, Dessie, Ethiopia;Ethiopian Federal Ministry of Health, Addis Ababa, Ethiopia;Institute for Global Health and Infectious Disease, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA;Malaria and Neglected Tropical Diseases Research Team, Bacterial, Parasitic and Zoonotic Disease Research Directorate, Ethiopian Public Health Institute, Addis Ababa, Ethiopia;Malaria and Neglected Tropical Diseases Research Team, Bacterial, Parasitic and Zoonotic Disease Research Directorate, Ethiopian Public Health Institute, Addis Ababa, Ethiopia;Institute for Global Health and Infectious Disease, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA;World Health Organization, Addis Ababa, Ethiopia;

关键词: Efficacy;    Ethiopia;    Hamusit;    P. falciparum;    Pyronaridine-artesunate;    Malaria;   

DOI  :  10.1186/s12936-023-04618-y

 received in 2023-04-05, accepted in 2023-06-09,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundEarly case detection and prompt treatment are important malaria control and elimination strategies. However, the emergence and rapid spread of drug-resistant strains present a major challenge. This study reports the first therapeutic efficacy profile of pyronaridine-artesunate against uncomplicated Plasmodium falciparum in Northwest Ethiopia.MethodsThis single-arm prospective study with 42-day follow-up period was conducted from March to May 2021 at Hamusit Health Centre using the World Health Organization (WHO) therapeutic efficacy study protocol. A total of 90 adults ages 18 and older with uncomplicated falciparum malaria consented and were enrolled in the study. A standard single-dose regimen of pyronaridine-artesunate was administered daily for 3 days, and clinical and parasitological outcomes were assessed over 42 days of follow-up. Thick and thin blood films were prepared from capillary blood and examined using light microscopy. Haemoglobin was measured and dried blood spots were collected on day 0 and on the day of failure.ResultsOut of 90 patients, 86/90 (95.6%) completed the 42-day follow-up study period. The overall PCR-corrected cure rate (adequate clinical and parasitological response) was very high at 86/87 (98.9%) (95% CI: 92.2–99.8%) with no serious adverse events. The parasite clearance rate was high with fast resolution of clinical symptoms; 86/90 (95.6%) and 100% of the study participants cleared parasitaemia and fever on day 3, respectively.ConclusionPyronaridine-artesunate was highly efficacious and safe against uncomplicated P. falciparum in this study population.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

13690_2023_1130_Article_IEq9.gif

13690_2023_1130_Article_IEq7.gif

Fig. 2

Fig. 5